Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-Invasive Minimal Residual Disease (MRD) Assessment in Multiple Myeloma Via Functional Imaging and Liquid Biopsy

NCT05625971 is registered in ClinicalTrials.gov with Rajshekhar Chakraborty, MD as lead sponsor.

NCT NCT05625971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05625971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-Invasive Minimal Residual Disease (MRD) Assessment in Multiple Myeloma Via Functional Imaging and Liquid Biopsy
Lead sponsor
Rajshekhar Chakraborty, MD
Phase
Observational
Overall status
Completed
Start date
September 14, 2022
Completion date
December 15, 2025
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma